Irene Pecora

Irene Pecora

Auto-generated profile, based on publicly available information

Irene Pecora

Unit of Medical Oncology, Ospedale Misericordia di Grosseto,Via Senese, 161, Grosseto, 58100, Italy

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
SCSilvia Catanese
Silvia Catanese
GAGiacomo Aringhieri
Giacomo Aringhieri
CVCaterina Vivaldi
Caterina Vivaldi
FSFrancesca Salani
Francesca Salani
SVSaverio Vitali
Saverio Vitali
LFLorenzo Fornaro
Lorenzo Fornaro
Sarcopenia is recognised as a predictor of toxicity and survival in localised and locally advanced gastric cancer (GC). Its prognostication power in advanced unresectable or metastatic GC (aGC) is debated. The survival impact of visceral and subcutaneous fat distribution (visceral fat area (VFA)/subcutaneous fat area (SFA)) is ambiguous. Our aim was to determine the influence of body composition parameters (BCp) on toxicity and survival in aGC patients undergoing palliative treatment. BCp were retrospectively assessed by baseline computed tomography for 78 aGC patients who received first-line chemotherapy from March 2010 to January 2017. Correlations between BCp and toxicity and survival were calculated by χ2-test and by log-rank-test and Cox-model, respectively. Sarcopenia fails to show association with progression-free survival (PFS) (p = 0.44) and overall survival (OS) (p = 0.88). However, sarcopenia influences the development of high-grade neutropenia (p = 0.048) and mucositis (p = 0.054). VFA/SFA (high vs. all the rest) results as a strong predictor of objective response (p = 0.02) and outcome (PFS, p = 0.001; OS, p = 0.02). At multivariate analysis for PFS, prognostic factors are VFA/SFA (p = 0.03) and a neutrophil–lymphocyte ratio >3. The same factors remain significant for OS (each p = 0.03) along with Eastern Cooperative Oncology Group (ECOG) performance status (p = 0.008) and number of metastatic sites ≥2 (p < 0.001). In our cohort of aGC, VFA/SFA exhibit a robust impact on survival, with a higher sensitivity than sarcopenia.

Verified
Journal Article
Open access
PDF file
CVCaterina Vivaldi
Caterina Vivaldi
SCSilvia Catanese
Silvia Catanese
VMValentina Massa
Valentina Massa
IPIrene Pecora
Irene Pecora
FSFrancesca Salani
Francesca Salani
LFLorenzo Fornaro
Lorenzo Fornaro
Esophageal cancer remains a challenging disease due to limited treatment options and poor prognosis. In recent years, immune checkpoint inhibitors (ICI) have been proven to be safe and effective in the treatment of highly lethal malignancies, such as non-small cell lung cancer and melanoma. Recent clinical trials also showed promising activity in immune checkpoint inhibitors in pretreated advanced esophageal carcinoma and a potentially significant impact on the outcome of selected patients, independently of histology. Combination studies evaluating immunotherapy and chemotherapy and, in localized disease, radiotherapy are in progress and will hopefully confirm their promises in the near future. However, reliable predictive biomarkers are still lacking. Indeed, at present, the role of programmed cell death ligand 1 expression and other factors (such as microsatellite instability and tumor mutational burden) as predictive biomarkers of benefit to immune checkpoint inhibitors is still controversial. Our aim was to explore the rationale of ICIs in esophageal cancer, review the results already available in multiple settings, and investigate future perspectives with single-agent and combination strategies.

4 July 2019 in Cancers
Verified
Journal Article
Open access
PDF file
CVCaterina Vivaldi
Caterina Vivaldi
LFLorenzo Fornaro
Lorenzo Fornaro
CCCarla Cappelli
Carla Cappelli
IPIrene Pecora
Irene Pecora
SCSilvia Catanese
Silvia Catanese
EVEnrico Vasile
Enrico Vasile
Early tumor shrinkage (ETS) and depth of response (DoR) predict favorable outcomes in metastatic colorectal cancer. We aim to evaluate their prognostic role in metastatic pancreatic cancer (PC) patients treated with first-line modified-FOLFIRINOX (FOLFOXIRI) or Gemcitabine + Nab-paclitaxel (GemNab). Hence, 138 patients were tested for ETS, defined as a ≥20% reduction in the sum of target lesions’ longest diameters (SLD) after 6–8 weeks from baseline, and DoR, i.e., the maximum percentage shrinkage in the SLD from baseline. Association of ETS and DoR with progression-free survival (PFS) and overall survival (OS) was assessed. ETS was reached in 49 patients (39.5% in the FOLFOXIRI, 29.8% in the GemNab group; p = 0.280). In the overall population, ETS was significantly associated with better PFS (8.0 vs. 4.8 months, p < 0.001) and OS (13.2 vs. 9.7 months, p = 0.001). Median DoR was −27.5% (−29.4% with FOLFOXIRI and −21.4% with GemNab, p = 0.016): DoR was significantly associated with better PFS (9.0 vs. 6.7 months, p < 0.001) and OS (14.3 vs. 11.1 months, p = 0.031). Multivariate analysis confirmed both ETS and DoR are independently associated with PFS and OS. In conclusion, our study added evidence on the role of ETS and DoR in the prediction of outcome of PC patients treated with first-line combination chemotherapy.

27 April 2022 in Epigenomics
Verified
Journal Article
Open access
FSFrancesca Salani
Francesca Salani
MLMaryam Latarani
Maryam Latarani
AGAndrea Casadei gardini
Andrea Casadei gardini
PGPriyadarsini Gangadharannambiar
Priyadarsini Gangadharannambiar
LFLorenzo Fornaro
Lorenzo Fornaro
FCFrancesco Crea
Francesco Crea
Background: Predictive biomarkers for advanced hepatocellular carcinoma are lacking. EZH2 drives sorafenib resistance through H3K27me3 and is counteracted by SETD2, which catalyzes H3K36me3. The au... Plain language summary Hepatocellular carcinoma (HCC) is responsible for approximately 10% of all cancer-related deaths worldwide. It is caused mainly by dysmetabolic syndrome, which is the presenc...

1 July 2020 in Annals of Oncology
Verified
Journal Article
Open access
PDF file
FSFrancesca Salani
Francesca Salani
IPI. Pecora
I. Pecora
CVCaterina Vivaldi
Caterina Vivaldi
VMV. Massa
V. Massa
SCS. Catanese
S. Catanese
Gianluca MasiGianluca Masi
Gianluca Masi
Background HCC-CC is the second most frequent subtype among rare pathological variants of HCC. Despite epidemiological, clinical, radiological and molecular peculiarities have been reported, neither dedicated treatment guidelines nor clinical trials are available for HCC-CC. Methods We retrospectively collected clinical and survival data from HCC-CC patients followed at our Institution from January 2015 to present. The primary aim of our study was to describe both patients’ baseline characteristics and outcomes in terms of progression-free survival (PFS) and overall survival (OS) according to disease stage and type of treatment. Estimations of time-to-event curves were generated by the Kaplan-Meier method. Results Among 138 HCC patients, 73 (52.9%) had a histologically confirmed diagnosis and 18 (13.0%) belonged to the HCC-CC subtype and were therefore included in the present analysis. Of the 18 HCC-CC patients, 16 (88.9%) were males and 2 females (11.1%), with a mean age at diagnosis of 67 years (range: 53-79). As for etiology, 9 (50.0%) cases recognized a dysmetabolic cause, 1 (5.5%) was HCV-related and 8 (44.5%) arose on healthy liver. All patients showed a preserved liver function (Child-Pugh A) at baseline. Regarding disease extension at diagnosis, 12 (66.7%) were in early stage (BCLC-A), 1 (5.5%) had intermediate (BCLC-B) and 5 (27.8%) advanced (BCLC-C) disease due to ECOG PS≥1. Sixteen patients (88.9%) underwent surgery as first treatment, while 1 case received liver transplantation and 1 received transarterial chemoembolization (TACE). At first evidence of progression, 4 patients were offered additional locoregional treatments: TACE in 2 cases, transarterial radioembolization and microwave ablation 1 case each. After a median interval of 9.1 months from initial curative-intent treatment, 10 (55.5%) patients progressed, 2 showing hepatic-only spread, 1 lung-only and and 7 ≥2 metastatic sites, i.e. liver (6), peritoneum (4), lung (2), skeletal, lymph nodes and skin (1 each). A systemic first-line therapy was administered to 7 metastatic patients, 6 of which were followed at our center: 4 received sorafenib and 2 received experimental treatment with durvalumab (1 patient) or lenvatinib plus pembrolizumab/placebo (1 patient). Disease progression was reported as best radiological response in 66.7% of cases. Notably, despite a median first-line PFS of 2.76 months (95% CI 1.38-5.03), most patients received subsequent systemic therapies (50% second-line, 20% third-line) and 20% were considered for surgery (peritonectomy with hypertermic intraperitoneal chemotherapy), reaching a survival rate of 100% and 60% at 6-months and 1-year respectively. Surgery was performed as only treatment in other 2 metastatic patients; of note, 1 of them underwent multiple excisions of extrahepatic localizations, reaching a 50.0 months survival at the time of analysis. Conclusion Our cohort of HCC-CC patients showed a predominantly non-viral etiology, a mainly early-stage at diagnosis with preserved liver function and a relatively favorable outcome even in metastatic patients, consistently with previously published data. Interestingly, we observed a poor efficacy of systemic treatment with tyrosine-kinase inhibitors, whereas surgery seemed to be effective even in the metastatic setting. Role of immune checkpoints inhibitors in HCC-CC should be further explored. Wider multicentric experiences are warranted to shed light on this not-so-rare HCC-subtype. Legal entity responsible for the study The authors. Funding Has not received any funding. Disclosure The presenting author has declared no conflicts of interest.

26 October 2026 in Surgical Oncology
Verified
Journal Article
Open access
CDChiara D'ALterio
Chiara D'ALterio
QLQuirino Lai
Quirino Lai
MLMaria Lanzone
Maria Lanzone
RVRoberto Valente
Roberto Valente
MCMatteo Fabbrici da Correggio
Matteo Fabbrici da Correggio
TCThalis Christophides
Thalis Christophides